Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) Mirum Pharmaceuticals, Inc. a leading rare disease company, today announced that Health Canada has authorized LIVMARLI® (maralixibat) oral solution and…
Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care Insulet Corporation the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its transformative Omnipod 5 Automated Insulin Delivery (AID) System is now…
Leyden Labs Demonstrates Feasibility of Novel Antibody-Based Nasal Spray for Flu Prevention Leyden Laboratories B.V. (the “Company” or “Leyden Labs”) today announced landmark preclinical and clinical data in Science Translational Medicine supporting the development of their antibody-based nasal sprays to prevent influenza…
Aya Locums’ Physician Assistant Named a “2025 Locum Tenens Providers of the Year” by Locumpedia Locumpedia named Alain Raymond, PA-C, a cardiothoracic surgical physician assistant with Aya Locums and a U.S. Navy veteran, as a “2025 Locum Tenens Providers of…
Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care Today, Hims & Hers Health, Inc. (NYSE: HIMS), the leading digital health and wellness platform, launched access to the Hims & Hers Multi-Cancer Test by Galleri®,…
Clarest Health Launches “Clarest at Home,” Closing the Gap in Medication Management from Facility to Front Door Clarest Health, a leader in personalized medication management, announced the launch of Clarest at Home, a comprehensive at-home medication care solution. This offering is…
Johnson & Johnson Showcases New Scientific Evidence and Strengthens Leadership Through Portfolio Innovations at AF Symposium Johnson & Johnson is announcing new portfolio innovations in addition to compelling clinical evidence in atrial fibrillation (AFib) at the 31st Annual AF Symposium in Boston.…
EYLEA HD® (aflibercept) 8 mg Data Presented at Angiogenesis 2026 Highlight Robust Clinical Profile in Treating Serious Retinal Diseases Regeneron Pharmaceuticals, Inc. today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration)…
Johnson & Johnson Secures CHMP Positive Opinion for AKEEGA®—a Dual-Action Tablet Combining Niraparib and Abiraterone Acetate—for Treating Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Patients with BRCA1/2 Mutations Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use…
WuXi Biologics and Sinorda Biomedicine Forge Strategic Partnership to Advance Development and Manufacturing of Innovative Bispecific Antibodies WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the…
Intellia Therapeutics Announces FDA Lifts Clinical Hold on MAGNITUDE-2 Phase 3 Trial for ATTRv-PN Intellia Therapeutics, Inc., a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has removed…
BioMarin Moves to Strengthen BalanceBioMarin Announces Proposed Private Offering of Senior Notes and New Senior Secured Term Loan Syndication BioMarin Pharmaceutical Inc. announced today that it intends to offer, subject to market and other conditions, $850 million of senior unsecured…